Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The cholinergic neurotransmission system is a vital signaling network that employs acetylcholine (ACh) as its primary neurotransmitter to facilitate communication within the central and peripheral nervous systems [1]. It is composed of various molecular entities, including the synthesizing enzyme choline acetyltransferase (ChAT), the hydrolyzing enzyme acetylcholinesterase (AChE), and two distinct receptor families: the ionotropic nicotinic receptors (nAChRs) and the metabotropic muscarinic receptors (mAChRs) [2]. This system is essential for regulating a wide array of functions, ranging from voluntary muscle movement and autonomic control to higher-order cognitive processes like memory, attention, and arousal [1, 3]. Pathological disruptions in cholinergic signaling are central to the etiology of neurodegenerative conditions such as Alzheimer's disease and neuromuscular disorders like myasthenia gravis [3, 4]. Therapeutic strategies often target specific components of this system, such as using AChE inhibitors to prolong the action of ACh in the synaptic cleft or utilizing receptor-specific agonists and antagonists to modulate physiological responses [2, 4]. Additionally, the system is a target for various toxins and chemical agents, such as organophosphates, which can lead to life-threatening cholinergic crises [1]. Understanding the spatial distribution and subtype specificity of cholinergic receptors remains a primary focus for developing precision medicines with fewer side effects [2]. Overall, the cholinergic system serves as a fundamental pillar of neural communication and a critical focus for pharmacological intervention in neurology and psychiatry [3].
Modulation of the system occurs through the inhibition of acetylcholinesterase (AChE) to prevent acetylcholine degradation, agonism or antagonism of nicotinic and muscarinic receptors, and the inhibition of acetylcholine release or vesicular transport [1, 2, 4].
9 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Cholinergic neurotransmission system.